A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer

AstraZeneca

Status and phase: Completed; Phase 3

Conditions: Gastrointestinal Hemorrhage

Treatments: Drug: Esomeprazole

Study type: Interventional

Funder types: Industry

Identifiers

NCT00251979

D961DC00001

Details and patient eligibility

About

This study is being carried out to see if constant 3 days infusion of Nexium is effective in preventing rebleeding after an endoscopic treatment.

Enrollment: 1,312 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signs of a bleeding in the stomach
• One endoscopically confirmed bleeding ulcer in the stomach or duodenum

Exclusion criteria

• Malignancy or other advanced disease.
• Major cardiovascular event.
• Severe hepatic disease

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind